Supplementary Figure 2 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Huafeng Wei,Hao Wang,Bing Lu,Bohua Li,Sheng Hou,Weizhu Qian,Kexing Fan,Jianxin Dai,Jian Zhao,Yajun Guo

DOI: https://doi.org/10.1158/0008-5472.22375074

2023-01-01

Abstract:Supplementary Figure 2 from Cancer Immunotherapy Using In vitro Genetically Modified Targeted Dendritic Cells

What problem does this paper attempt to address?

Supplementary Figure Legends 1-4 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Huafeng Wei,Hao Wang,Bing Lu,Bohua Li,Sheng Hou,Weizhu Qian,Kexing Fan,Jianxin Dai,Jian Zhao,Yajun Guo

DOI: https://doi.org/10.1158/0008-5472.22375065.v1

2023-01-01

Abstract:Supplementary Figure Legends 1-4 from Cancer Immunotherapy Using In vitro Genetically Modified Targeted Dendritic Cells
Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Wenqun Zhong,Zebin Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23907869

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Xiaohui Fan,Randall J. Brezski,Hui Deng,Pooja Dhupkar,Yun Q. Shi,Anneliese Gonzalez,Songlin Zhang,Michael A. Rycyzyn,William R. Strohl,Robert E. Jordan,Ningyan Zhang,Zhiqiang An

DOI: https://doi.org/10.1158/1535-7163.22501711

2023-01-01

Abstract:Figure S1: IdeS expression in BT474 breast cancer cells Figure S2: Detection of MMPs in cancer cell lysates and culture supernatant Figure S3: scIgG-T was not in the SKBR-3 cell culture medium Figure S4: Detection of immune cells infiltration in mice by flow cytometry.
Supplementary Figure 2 from In Situ Vaccination with CD204 Gene-Silenced Dendritic Cell, not Unmodified Dendritic Cell, Enhances Radiation Therapy of Prostate Cancer

Chunqing Guo,Huanfa Yi,Xiaofei Yu,Daming Zuo,Jie Qian,Gary Yang,Barbara A. Foster,John R. Subjeck,Xiaolei Sun,Ross B. Mikkelsen,Paul B. Fisher,Xiang-Yang Wang

DOI: https://doi.org/10.1158/1535-7163.22497105.v1

2023-01-01

Abstract:PDF file, 1232K, SRA/CD204-targeted radio-immunotherapy enhances cytolytic activity of effector T cells.
Supplemental Figure S3 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402079

2023-01-01

Abstract:Identification of established CCDC134 transgenic mice.
Supplementary Data from Targeted Delivery of Tumor Antigens to Activated Dendritic Cells Via CD11c Molecules Induces Potent Antitumor Immunity in Mice

Huafeng Wei,Suhui Wang,David Zhang,Sheng Hou,Weizhu Qian,Bohua Li,Haipeng Guo,Geng Kou,Jian He,Hao Wang,Yajun Guo

DOI: https://doi.org/10.1158/1078-0432.22440507

2023-01-01

Abstract:Supplementary Data from Targeted Delivery of Tumor Antigens to Activated Dendritic Cells via CD11c Molecules Induces Potent Antitumor Immunity in Mice
Supplementary Figure 2 from Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy

Jun Zhao,Mark Z. Ma,Hening Ren,Zhenqiu Liu,Martin J. Edelman,Hong Pan,Li Mao

DOI: https://doi.org/10.1158/1078-0432.22452492.v1

2023-01-01

Abstract:Supplementary Figure 2 - PDF file 693K, Notch intracellular domain IHC
Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Zhiliang Ma,Wen Li,Shinichi Yoshiya,Yong Xu,Masaki Hara,Yosif El‐Darawish,Tzvetanka Markova,Kyosuke Yamanishi,Hiromichi Yamanishi,Hideaki Tahara,Yoshimasa Tanaka,Haruki Okamura

DOI: https://doi.org/10.1158/1078-0432.22459815.v1

2023-01-01

Abstract:Cytotoxic activity exhibited by PECs from pre-implanted mice receiving immune checkpoint blockade and/or IL-18
Supplemental Figure S4 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402076.v1

2023-01-01

Abstract:Potent antitumor activity of CCDC134 in vivo.
supplementary figure 1 from Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study

Jiazuan Ni,Guoliang Qiao,Xiaoli Wang,Michael A. Morse,William R. Gwin,Lian Zhou,Yang Song,Yu-Guo Zhao,Feng Chen,Xinna Zhou,Lihui Huang,Amy Hobeika,Xin Yi,Xuefeng Xia,Yanfang Guan,Song Jiang,Jing Ren,H. Kim Lyerly

DOI: https://doi.org/10.1158/1078-0432.22466309.v1

2023-01-01

Abstract:Comparison of frequency of cfDNA
Supplemental Data from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402070.v1

2023-01-01

Abstract:Supplemental materials and methods and legends for all supplemental figures.
Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Huafeng Wei,Hao Wang,Bing Lu,Bohua Li,Sheng Hou,Weizhu Qian,Kexing Fan,Jianxin Dai,Jian Zhao,Yajun Guo

DOI: https://doi.org/10.1158/0008-5472.can-07-6051

IF: 11.2

2008-01-01

Cancer Research

Abstract:Modest clinical outcomes of dendritic cell (DC) vaccine trials call for novel strategies. In this study, we have created a chimeric CD40 molecule that incorporates a single chain Fv (scFv) molecule specific for human ErbB2 antigen and fusing to the membrane spanning and cytosolic domains of murine CD40. After adenoviral transfer to bone marrow-derived DC, this chimeric receptor (CR) induced nuclear factor-kappaB (NF-kappaB)-dependent DC activation and effector function when cultured with immobilized ErbB2 protein or ErbB2-positive tumor cells in vitro. In vivo migration assays showed that approximately 40% injected CR-modified DC (scFv-CD40-DC) effectively migrated to ErbB2-positive tumors, where they were activated after ErbB2 antigen stimulation, and sequentially homed into the draining lymph nodes. In murine ErbB2-positive D2F2/E2 breast tumor (BALB/c) and EL4/E2 thymoma (C57BL/6) models, i.v. injection of 1 x 10(6) scFv-CD40-DC significantly inhibited tumor growth and cured established tumors. Importantly, the cured mice treated by injection of scFv-CD40-DC were effective in preventing both ErbB2-positive and parental ErbB2-negative tumor rechallenge. Analysis of the underlying mechanism revealed that i.v. infusion of scFv-CD40-DC elicited tumor-specific CTL responses, and the transfer of CTLs from scFv-CD40-DC-treated mice protected naive mice against a subsequent tumor challenge. These results support the concept that genetic modification of DC with tumor-associated antigen-specific CD40 chimeric receptor might be a useful strategy for treatment of human cancers.
Supplemental Figure S5 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402073

2023-01-01

Abstract:Involvement of CD4+ T cells in the induction of antitumor activity by CCDC134.
Supplementary Figure 4 from Antigen Priming Induces Functional Reprogramming in Inkt Cells Via Metabolic and Epigenetic Regulation: an Insight into Inkt Cell-Based Antitumor Immunotherapy

Huimin Zhang,Sanwei Chen,Yuwei Zhang,Chenxi Tian,Jun Pan,Yu Wang,Shiyu Bai,Qielan Wu,Miya Su,Di Xie,Sicheng Fu,Shuhang Li,Jing Zhang,Yusheng Chen,Shasha Zhu,Yeben Qian,Li Bai

DOI: https://doi.org/10.1158/2326-6066.24709791

2023-01-01

Abstract:Gating strategy for identifying different lymphocytes in tumors.
Supplemental Figure S1 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402085

2023-01-01

Abstract:Homo sapiens and Mus musculus CCDC134 are highly similar.
Supplemental Figure Legends from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Enxiu Wang,Liang-Chuan Wang,Ching-Yi Tsai,Vijay Bhoj,Zack Gershenson,Edmund K. Moon,Kheng Newick,Jing Sun,Albert Lo,Timothy Baradet,Michael D. Feldman,David M. Barrett,Ellen Puré,Steven Μ. Albelda,Michael C. Milone

DOI: https://doi.org/10.1158/2326-6066.22538600.v1

2023-01-01

Abstract:Figure legends for supplemental data.
Supplementary Figure S6 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Jason Bugno,Liangliang Wang,Xianbin Yu,Xuezhi Cao,Jiaai Wang,Xiaona Huang,Kaiting Yang,Andras Piffko,Katherine Chen,Stephen Y. Luo,Emile Naccasha,Yuzhu Hou,Sherry Fu,Chuan He,Yang-xin Fu,Hua L. Liang,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/1078-0432.27142126

2024-01-01

Abstract:Supplementary Figure S6. Treg tumor infiltration after local RT in MC38 tumors and splenic cDC isolation strategy.
Supplementary Figure 4 from in Situ Vaccination with CD204 Gene-Silenced Dendritic Cell, Not Unmodified Dendritic Cell, Enhances Radiation Therapy of Prostate Cancer

Chunqing Guo,Huanfa Yi,Xiaofei Yu,Daming Zuo,Jie Qian,Gary Yang,Barbara A. Foster,John R. Subjeck,Xiaolei Sun,Ross B. Mikkelsen,Paul B. Fisher,Xiang-Yang Wang

DOI: https://doi.org/10.1158/1535-7163.22497099.v1

2023-01-01

Abstract:PDF file, 1187K, DC-SRA shRNA vaccination following RT upregulates Granzyme B expression in tumor-infiltrating CD8+ cells.
Supplementary Figure from the Antitumor Effects of Vaccine-Activated CD8+ T Cells Associate with Weak TCR Signaling and Induction of Stem-Like Memory T Cells

Sha Wu,Wei Zhu,Yibing Peng,Lan Wang,Yuan Hong,Lei Huang,Dayong Dong,Junping Xie,Todd Merchen,Edward Kruse,Zong Sheng Guo,David Bartlett,Ning Fu,Yukai He

DOI: https://doi.org/10.1158/2326-6066.cir-17-0016

IF: 10.1

2017-01-01

Cancer Immunology Research

Abstract:Supplementary Figure from The Antitumor Effects of Vaccine-Activated CD8+ T Cells Associate with Weak TCR Signaling and Induction of Stem-Like Memory T Cells

Supplementary Figure 2 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Supplementary Figure Legends 1-4 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Figure 2 from <i>In Situ</i> Vaccination with <i>CD204</i> Gene-Silenced Dendritic Cell, not Unmodified Dendritic Cell, Enhances Radiation Therapy of Prostate Cancer

Supplemental Figure S3 from Cytokine-like Molecule CCDC134 Contributes to CD8<sup>+</sup> T-cell Effector Functions in Cancer Immunotherapy

Supplementary Data from Targeted Delivery of Tumor Antigens to Activated Dendritic Cells Via CD11c Molecules Induces Potent Antitumor Immunity in Mice

Supplementary Figure 2 from Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Supplemental Figure S4 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

supplementary figure 1 from Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study

Supplemental Data from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Supplemental Figure S5 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Supplementary Figure 4 from Antigen Priming Induces Functional Reprogramming in Inkt Cells Via Metabolic and Epigenetic Regulation: an Insight into Inkt Cell-Based Antitumor Immunotherapy

Supplemental Figure S1 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Supplemental Figure Legends from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Supplementary Figure S6 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Figure 4 from in Situ Vaccination with CD204 Gene-Silenced Dendritic Cell, Not Unmodified Dendritic Cell, Enhances Radiation Therapy of Prostate Cancer

Supplementary Figure from the Antitumor Effects of Vaccine-Activated CD8+ T Cells Associate with Weak TCR Signaling and Induction of Stem-Like Memory T Cells

Supplementary Figure 2 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Supplementary Figure Legends 1-4 from Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Figure 2 from <i>In Situ</i> Vaccination with <i>CD204</i> Gene-Silenced Dendritic Cell, not Unmodified Dendritic Cell, Enhances Radiation Therapy of Prostate Cancer

Supplemental Figure S3 from Cytokine-like Molecule CCDC134 Contributes to CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Effector Functions in Cancer Immunotherapy

Supplementary Data from Targeted Delivery of Tumor Antigens to Activated Dendritic Cells Via CD11c Molecules Induces Potent Antitumor Immunity in Mice

Supplementary Figure 2 from Anti-HDGF Targets Cancer and Cancer Stromal Stem Cells Resistant to Chemotherapy

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Supplemental Figure S4 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

supplementary figure 1 from Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study

Supplemental Data from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Supplemental Figure S5 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Supplementary Figure 4 from Antigen Priming Induces Functional Reprogramming in Inkt Cells Via Metabolic and Epigenetic Regulation: an Insight into Inkt Cell-Based Antitumor Immunotherapy

Supplemental Figure S1 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Supplemental Figure Legends from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors

Supplementary Figure S6 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Figure 4 from in Situ Vaccination with CD204 Gene-Silenced Dendritic Cell, Not Unmodified Dendritic Cell, Enhances Radiation Therapy of Prostate Cancer

Supplementary Figure from the Antitumor Effects of Vaccine-Activated CD8+ T Cells Associate with Weak TCR Signaling and Induction of Stem-Like Memory T Cells

Supplemental Figure S3 from Cytokine-like Molecule CCDC134 Contributes to CD8<sup>+</sup> T-cell Effector Functions in Cancer Immunotherapy